View in EDS HTML Full Text PDF Full Text

Mechanisms of resistance to VHL loss-induced genetic and pharmacological vulnerabilities.

Saved in:
Bibliographic Details
Title: Mechanisms of resistance to VHL loss-induced genetic and pharmacological vulnerabilities.
Authors: Ge J; MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, UK.; Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK., Hirosue S; MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, UK., Castillon L; Translational Cancer Medicine Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Patel SA; MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, UK.; Wellcome Sanger Institute, Cambridge, UK., Wesolowski L; MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, UK., Dyas A; MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, UK.; Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK., Yong C; Department of Surgery, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., de Haan S; Princess Máxima Center for Pediatric Oncology, Oncode Institute, Heidelberglaan 25, Utrecht, 3584 CS, The Netherlands., Drost J; Princess Máxima Center for Pediatric Oncology, Oncode Institute, Heidelberglaan 25, Utrecht, 3584 CS, The Netherlands.; Division of Cell Biology, Metabolism & Cancer, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands., Stewart GD; Department of Surgery, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK., Obenauf AC; Research Institute of Molecular Pathology, Vienna Biocenter, Vienna, Austria., Muñoz-Espín D; Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK. dm742@cam.ac.uk.; Thoracic Cancer Programme, CRUK Cambridge Centre, Cambridge, UK. dm742@cam.ac.uk., Vanharanta S; MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, UK. sakari.vanharanta@helsinki.fi.; Translational Cancer Medicine Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland. sakari.vanharanta@helsinki.fi.; Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, Helsinki, Finland. sakari.vanharanta@helsinki.fi.
Source: EMBO molecular medicine [EMBO Mol Med] 2026 Feb; Vol. 18 (2), pp. 599-619. Date of Electronic Publication: 2025 Dec 19.
Publication Type: Journal Article
Journal Info: Publisher: EMBO Press Country of Publication: Germany NLM ID: 101487380 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1757-4684 (Electronic) Linking ISSN: 17574676 NLM ISO Abbreviation: EMBO Mol Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41420106
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Mechanisms of resistance to VHL loss-induced genetic and pharmacological vulnerabilities.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Ge+J%22">Ge J</searchLink>; MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, UK.; Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Hirosue+S%22">Hirosue S</searchLink>; MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Castillon+L%22">Castillon L</searchLink>; Translational Cancer Medicine Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Patel+SA%22">Patel SA</searchLink>; MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, UK.; Wellcome Sanger Institute, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Wesolowski+L%22">Wesolowski L</searchLink>; MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Dyas+A%22">Dyas A</searchLink>; MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, UK.; Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Yong+C%22">Yong C</searchLink>; Department of Surgery, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22de+Haan+S%22">de Haan S</searchLink>; Princess Máxima Center for Pediatric Oncology, Oncode Institute, Heidelberglaan 25, Utrecht, 3584 CS, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Drost+J%22">Drost J</searchLink>; Princess Máxima Center for Pediatric Oncology, Oncode Institute, Heidelberglaan 25, Utrecht, 3584 CS, The Netherlands.; Division of Cell Biology, Metabolism & Cancer, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Stewart+GD%22">Stewart GD</searchLink>; Department of Surgery, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Obenauf+AC%22">Obenauf AC</searchLink>; Research Institute of Molecular Pathology, Vienna Biocenter, Vienna, Austria.<br /><searchLink fieldCode="AU" term="%22Muñoz-Espín+D%22">Muñoz-Espín D</searchLink>; Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK. dm742@cam.ac.uk.; Thoracic Cancer Programme, CRUK Cambridge Centre, Cambridge, UK. dm742@cam.ac.uk.<br /><searchLink fieldCode="AU" term="%22Vanharanta+S%22">Vanharanta S</searchLink>; MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, UK. sakari.vanharanta@helsinki.fi.; Translational Cancer Medicine Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland. sakari.vanharanta@helsinki.fi.; Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, Helsinki, Finland. sakari.vanharanta@helsinki.fi.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101487380%22">EMBO molecular medicine</searchLink> [EMBO Mol Med] 2026 Feb; Vol. 18 (2), pp. 599-619. <i>Date of Electronic Publication: </i>2025 Dec 19.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22EMBO+Press%22">EMBO Press </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>101487380 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1757-4684 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2217574676%22">17574676 </searchLink><i>NLM ISO Abbreviation: </i>EMBO Mol Med <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41420106
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s44321-025-00361-w
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 599
    Titles:
      – TitleFull: Mechanisms of resistance to VHL loss-induced genetic and pharmacological vulnerabilities.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ge J
      – PersonEntity:
          Name:
            NameFull: Hirosue S
      – PersonEntity:
          Name:
            NameFull: Castillon L
      – PersonEntity:
          Name:
            NameFull: Patel SA
      – PersonEntity:
          Name:
            NameFull: Wesolowski L
      – PersonEntity:
          Name:
            NameFull: Dyas A
      – PersonEntity:
          Name:
            NameFull: Yong C
      – PersonEntity:
          Name:
            NameFull: de Haan S
      – PersonEntity:
          Name:
            NameFull: Drost J
      – PersonEntity:
          Name:
            NameFull: Stewart GD
      – PersonEntity:
          Name:
            NameFull: Obenauf AC
      – PersonEntity:
          Name:
            NameFull: Muñoz-Espín D
      – PersonEntity:
          Name:
            NameFull: Vanharanta S
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: 2026 Feb
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1757-4684
          Numbering:
            – Type: volume
              Value: 18
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: EMBO molecular medicine
              Type: main
ResultId 1